Radar Telegram alerts Open Radar

AriBio Oral AR1001 meets the primary efficacy endpoint in a prespecified phase 3 monotherapy population in the POLARIS-AD trial.

תרגם לעברית

Business Insider Markets · · Source

AriBio Oral AR1001 meets the primary efficacy endpoint in a prespecified phase 3 monotherapy population in the POLARIS-AD trial.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram